Cytokine storm syndrome in coronavirus disease 2019: A narrative review
-
- Y.‐M. Gao
- From the Institute of Nephrology Zhongda Hospital Southeast University School of Medicine Nanjing China
-
- G. Xu
- Department of Nephrology Tongji Hospital University of HuaZhong Science and Technology Wuhan China
-
- B. Wang
- From the Institute of Nephrology Zhongda Hospital Southeast University School of Medicine Nanjing China
-
- B.‐C. Liu
- From the Institute of Nephrology Zhongda Hospital Southeast University School of Medicine Nanjing China
抄録
<jats:title>Abstract</jats:title><jats:p>Cytokine storm syndrome (CSS) is a critical clinical condition induced by a cascade of cytokine activation, characterized by overwhelming systemic inflammation, hyperferritinaemia, haemodynamic instability and multiple organ failure (MOF). At the end of 2019, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) emerged in Wuhan, China, and rapidly developed into a global pandemic. More and more evidence shows that there is a dramatic increase of inflammatory cytokines in patients with COVID‐19, suggesting the existence of cytokine storm in some critical illness patients. Here, we summarize the pathogenesis, clinical manifestation of CSS, and highlight the current understanding about the recognition and potential therapeutic options of CSS in COVID‐19.</jats:p>
収録刊行物
-
- Journal of Internal Medicine
-
Journal of Internal Medicine 289 (2), 147-161, 2020-07-22
Wiley